サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1706795

アルカプトン尿症治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2025-2035年

Alkaptonuria Therapeutics Market (Drug Type: Nitisinone, Pain Relief Medication and Dietary Supplements; Route of Administration: Oral, Topical and Parenteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035

出版日
ページ情報
英文 236 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
アルカプトン尿症治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2025-2035年
出版日: 2025年02月19日
発行: Transparency Market Research
ページ情報: 英文 236 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アルカプトン尿症治療薬市場- 調査範囲

TMRの調査レポート「世界のアルカプトン尿症治療薬市場」は、2025年から2035年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2025年を基準年、2035年を予測年として、2019年から2035年までの世界のアルカプトン尿症治療薬市場の収益と予測を提供します。また、2025年から2035年までの世界のアルカプトン尿症治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、アルカプトン尿症治療薬市場を推察しました。

市場スナップショット
2024年の市場規模 1,470万米ドル
2035年の市場規模 3,160万米ドル
CAGR 7.2%

当レポートでは、世界のアルカプトン尿症治療薬市場の競合情勢について調査しています。世界のアルカプトン尿症治療薬市場で事業を展開する主要企業が特定され、各企業がさまざまな属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界のアルカプトン尿症治療薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー： 世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界のアルカプトン尿症治療薬市場の市場分析と予測, 2020-2035年

第5章 主要洞察

  • 主要地域/国におけるヘルスケア費支出
  • 主要地域/国におけるアルカプトン尿症の疫学
  • アルカプトン尿症治療アルゴリズム
  • 主要地域/国における規制シナリオ
  • 臨床試験分析
  • ポーターのファイブフォース分析
  • PESTEL分析
  • アルカプトン尿症治療におけるアンメットニーズ
  • 新規市場参入者のための市場開拓戦略
  • 主要な業界イベント（パートナーシップ、コラボレーション、製品承認、合併および買収）

第6章 世界の市場分析と予測：薬剤の種類別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測薬剤の種類別, 2020-2035年
    • ニチシノン（p-ヒドロキシフェニルピルビン酸ジオキシゲナーゼ阻害剤）
    • 鎮痛薬
    • 栄養補助食品
  • 医薬品の種類別の市場の魅力

第7章 世界の市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：投与経路別, 2020-2035年
    • オーラル
    • トピック
    • 非経口
  • 投与経路別の市場の魅力

第8章 世界の市場分析と予測：患者の年齢層別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：患者の年齢層別, 2020-2035年
    • 小児
    • 成人
    • 高齢者
  • 患者年齢層別の市場の魅力

第9章 世界の市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：流通チャネル別, 2020-2035年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別市場の魅力

第10章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 地域別市場の魅力

第11章 北米の市場分析と予測

  • 米国
  • カナダ

第12章 欧州の市場分析と予測

  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域

第13章 アジア太平洋地域の市場分析と予測

  • 中国
  • 日本
  • インド
  • オーストラリアとニュージーランド
  • その他アジア太平洋地域

第14章 ラテンアメリカの市場分析と予測

  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域

第15章 中東・アフリカの市場分析と予測

  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層別・規模別）
  • 市場シェア分析企業別（2024）
  • 企業プロファイル
    • Swedish Orphan Biovitrum AB
    • Eton Pharmaceuticals
    • Johnson & Johnson Services, Inc.
    • Pfizer Inc.
    • GSK plc
    • Sanofi
    • Mallinckrodt Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd.
    • Bristol Myers Squibb
    • Sun Pharmaceutical Industries Ltd.
    • Cipla
    • Dr. Reddy's Laboratories Ltd.
図表

List of Tables

  • Table 01: Global Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 02: Global Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2035
  • Table 03: Global Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Patient Age Group, 2020-2035
  • Table 04: Global Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 05: Global Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Region, 2020-2035
  • Table 06: North America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, by Country, 2020-2035
  • Table 07: North America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 08: North America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2035
  • Table 09: North America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Patient Age Group, 2020-2035
  • Table 10: North America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 11: Europe - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 12: Europe - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 13: Europe - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2035
  • Table 14: Europe - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Patient Age Group, 2020-2035
  • Table 15: Europe - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 16: Asia Pacific - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 17: Asia Pacific - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 18: Asia Pacific - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2035
  • Table 19: Asia Pacific - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Patient Age Group, 2020-2035
  • Table 20: Asia Pacific - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 21: Latin America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 22: Asia Pacific - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 23: Latin America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2035
  • Table 24: Latin America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Patient Age Group, 2020-2035
  • Table 25: Latin America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035
  • Table 26: Middle East & Africa - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020-2035
  • Table 27: Middle East & Africa - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Drug Type, 2020-2035
  • Table 28: Middle East & Africa - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2035
  • Table 29: Middle East & Africa - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Patient Age Group, 2020-2035
  • Table 30: Middle East & Africa - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, By Distribution Channel, 2020-2035

List of Figures

  • Figure 01: Global Alkaptonuria Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 02: Global Alkaptonuria Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 03: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Nitisinone (p-hydroxyphenyl-pyruvate dioxygenase inhibitor), 2020-2035
  • Figure 04: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Pain Relief Medication, 2020-2035
  • Figure 05: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Dietary Supplements, 2020-2035
  • Figure 06: Global Alkaptonuria Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 07: Global Alkaptonuria Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 08: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Oral, 2020-2035
  • Figure 09: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Topical, 2020-2035
  • Figure 10: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Parenteral, 2020-2035
  • Figure 11: Global Alkaptonuria Therapeutics Market Value Share Analysis, By Patient Age Group, 2024 and 2035
  • Figure 12: Global Alkaptonuria Therapeutics Market Attractiveness Analysis, By Patient Age Group, 2025-2035
  • Figure 13: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Pediatric, 2020-2035
  • Figure 14: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Adult, 2020-2035
  • Figure 15: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Geriatric, 2020-2035
  • Figure 16: Global Alkaptonuria Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 17: Global Alkaptonuria Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 18: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Hospital Pharmacies, 2020-2035
  • Figure 19: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Retail Pharmacies, 2020-2035
  • Figure 20: Global Alkaptonuria Therapeutics Market Revenue (US$ Mn), by Online Pharmacies, 2020-2035
  • Figure 21: Global Alkaptonuria Therapeutics Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 22: Global Alkaptonuria Therapeutics Market Attractiveness Analysis, By Region, 2025-2035
  • Figure 23: North America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 24: North America - Alkaptonuria Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 25: North America - Alkaptonuria Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 26: North America - Alkaptonuria Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 27: North America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 28: North America - Alkaptonuria Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 29: North America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 30: North America - Alkaptonuria Therapeutics Market Value Share Analysis, By Patient Age Group, 2024 and 2035
  • Figure 31: North America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Patient Age Group, 2025-2035
  • Figure 32: North America - Alkaptonuria Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 33: North America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 34: Europe - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 35: Europe - Alkaptonuria Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 36: Europe - Alkaptonuria Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
  • Figure 37: Europe - Alkaptonuria Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 38: Europe - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 39: Europe - Alkaptonuria Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 40: Europe - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 41: Europe - Alkaptonuria Therapeutics Market Value Share Analysis, By Patient Age Group, 2024 and 2035
  • Figure 42: Europe - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Patient Age Group, 2025-2035
  • Figure 43: Europe - Alkaptonuria Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 44: Europe - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 45: Asia Pacific - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 46: Asia Pacific - Alkaptonuria Therapeutics Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 47: Asia Pacific - Alkaptonuria Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2025-2035
  • Figure 48: Asia Pacific - Alkaptonuria Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 49: Asia Pacific - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 50: Asia Pacific - Alkaptonuria Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 51: Asia Pacific - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 52: Asia Pacific - Alkaptonuria Therapeutics Market Value Share Analysis, By Patient Age Group, 2024 and 2035
  • Figure 53: Asia Pacific - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Patient Age Group, 2025-2035
  • Figure 54: Asia Pacific - Alkaptonuria Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 55: Asia Pacific - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 56: Latin America - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 57: Latin America - Alkaptonuria Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 58: Latin America - Alkaptonuria Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
  • Figure 59: Latin America - Alkaptonuria Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 60: Latin America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 61: Latin America - Alkaptonuria Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 62: Latin America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 63: Latin America - Alkaptonuria Therapeutics Market Value Share Analysis, By Patient Age Group, 2024 and 2035
  • Figure 64: Latin America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Patient Age Group, 2025-2035
  • Figure 65: Latin America - Alkaptonuria Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 66: Latin America - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 67: Middle East & Africa - Alkaptonuria Therapeutics Market Value (US$ Mn) Forecast, 2020-2035
  • Figure 68: Middle East & Africa - Alkaptonuria Therapeutics Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 69: Middle East & Africa - Alkaptonuria Therapeutics Market Attractiveness Analysis, by Country / Sub-region, 2025-2035
  • Figure 70: Middle East & Africa - Alkaptonuria Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 71: Middle East & Africa - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 72: Middle East & Africa - Alkaptonuria Therapeutics Market Value Share Analysis, By Route of Administration, 2024 and 2035
  • Figure 73: Middle East & Africa - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Route of Administration, 2025-2035
  • Figure 74: Middle East & Africa - Alkaptonuria Therapeutics Market Value Share Analysis, By Patient Age Group, 2024 and 2035
  • Figure 75: Middle East & Africa - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Patient Age Group, 2025-2035
  • Figure 76: Middle East & Africa - Alkaptonuria Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 77: Middle East & Africa - Alkaptonuria Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
目次
Product Code: TMRGL86459

Alkaptonuria Therapeutics Market - Scope of Report

TMR's report on the global alkaptonuria therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global alkaptonuria therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global alkaptonuria therapeutics market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the alkaptonuria therapeutics market.

Market Snapshot
Market Value in 2024US$ 14.7 Mn
Market Value in 2035US$ 31.6 Mn
CAGR7.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global alkaptonuria therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global alkaptonuria therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global alkaptonuria therapeutics market.

The report delves into the competitive landscape of the global alkaptonuria therapeutics market. Key players operating in the global alkaptonuria therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global alkaptonuria therapeutics market profiled in this report.

Key Questions Answered in Global alkaptonuria therapeutics Market Report:

  • What is the sales/revenue generated by alkaptonuria therapeutics across all regions during the forecast period?
  • What are the opportunities in the global alkaptonuria therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Alkaptonuria Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global alkaptonuria therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global alkaptonuria therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global alkaptonuria therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Alkaptonuria Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Alkaptonuria Therapeutics Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Healthcare Expenditure across Key Regions / Countries
  • 5.2. Epidemiology of Alkaptonuria across Key Regions / Countries
  • 5.3. Alkaptonuria Treatment Algorithm
  • 5.4. Regulatory Scenario across Key Regions / Countries
  • 5.5. Clinical Trial Analysis
  • 5.6. PORTER's Five Forces Analysis
  • 5.7. PESTEL Analysis
  • 5.8. Unmet Needs in Alkaptonuria Treatment
  • 5.9. Go-to-Market Strategy for New Market Entrants
  • 5.10. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)

6. Global Alkaptonuria Therapeutics Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2020-2035
    • 6.3.1. Nitisinone (p-hydroxyphenyl-pyruvate dioxygenase inhibitor)
    • 6.3.2. Pain Relief Medication
    • 6.3.3. Dietary Supplements
  • 6.4. Market Attractiveness By Drug Type

7. Global Alkaptonuria Therapeutics Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020-2035
    • 7.3.1. Oral
    • 7.3.2. Topical
    • 7.3.3. Parenteral
  • 7.4. Market Attractiveness By Route of Administration

8. Global Alkaptonuria Therapeutics Market Analysis and Forecasts, By Patient Age Group

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Patient Age Group, 2020-2035
    • 8.3.1. Pediatric
    • 8.3.2. Adult
    • 8.3.3. Geriatric
  • 8.4. Market Attractiveness By Patient Age Group

9. Global Alkaptonuria Therapeutics Market Analysis and Forecasts, By Distribution Channel

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By Distribution Channel, 2020-2035
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness By Distribution Channel

10. Global Alkaptonuria Therapeutics Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Alkaptonuria Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2020-2035
    • 11.2.1. Nitisinone (p-hydroxyphenyl-pyruvate dioxygenase inhibitor)
    • 11.2.2. Pain Relief Medication
    • 11.2.3. Dietary Supplements
  • 11.3. Market Value Forecast By Route of Administration, 2020-2035
    • 11.3.1. Oral
    • 11.3.2. Topical
    • 11.3.3. Parenteral
  • 11.4. Market Value Forecast By Patient Age Group, 2020-2035
    • 11.4.1. Pediatric
    • 11.4.2. Adult
    • 11.4.3. Geriatric
  • 11.5. Market Value Forecast By Distribution Channel, 2020-2035
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Retail Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast By Country, 2020-2035
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Patient Age Group
    • 11.7.4. By Distribution Channel
    • 11.7.5. By Country

12. Europe Alkaptonuria Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2020-2035
    • 12.2.1. Nitisinone (p-hydroxyphenyl-pyruvate dioxygenase inhibitor)
    • 12.2.2. Pain Relief Medication
    • 12.2.3. Dietary Supplements
  • 12.3. Market Value Forecast By Route of Administration, 2020-2035
    • 12.3.1. Oral
    • 12.3.2. Topical
    • 12.3.3. Parenteral
  • 12.4. Market Value Forecast By Patient Age Group, 2020-2035
    • 12.4.1. Pediatric
    • 12.4.2. Adult
    • 12.4.3. Geriatric
  • 12.5. Market Value Forecast By Distribution Channel, 2020-2035
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Retail Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast By Country / Sub-region, 2020-2035
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Spain
    • 12.6.5. Italy
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Patient Age Group
    • 12.7.4. By Distribution Channel
    • 12.7.5. By Country / Sub-region

13. Asia Pacific Alkaptonuria Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020-2035
    • 13.2.1. Nitisinone (p-hydroxyphenyl-pyruvate dioxygenase inhibitor)
    • 13.2.2. Pain Relief Medication
    • 13.2.3. Dietary Supplements
  • 13.3. Market Value Forecast By Route of Administration, 2020-2035
    • 13.3.1. Oral
    • 13.3.2. Topical
    • 13.3.3. Parenteral
  • 13.4. Market Value Forecast By Patient Age Group, 2020-2035
    • 13.4.1. Pediatric
    • 13.4.2. Adult
    • 13.4.3. Geriatric
  • 13.5. Market Value Forecast By Distribution Channel, 2020-2035
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Retail Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast By Country / Sub-region, 2020-2035
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Patient Age Group
    • 13.7.4. By Distribution Channel
    • 13.7.5. By Country / Sub-region

14. Latin America Alkaptonuria Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020-2035
    • 14.2.1. Nitisinone (p-hydroxyphenyl-pyruvate dioxygenase inhibitor)
    • 14.2.2. Pain Relief Medication
    • 14.2.3. Dietary Supplements
  • 14.3. Market Value Forecast By Route of Administration, 2020-2035
    • 14.3.1. Oral
    • 14.3.2. Topical
    • 14.3.3. Parenteral
  • 14.4. Market Value Forecast By Patient Age Group, 2020-2035
    • 14.4.1. Pediatric
    • 14.4.2. Adult
    • 14.4.3. Geriatric
  • 14.5. Market Value Forecast By Distribution Channel, 2020-2035
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Retail Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast By Country / Sub-region, 2020-2035
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Patient Age Group
    • 14.7.4. By Distribution Channel
    • 14.7.5. By Country / Sub-region

15. Middle East & Africa Alkaptonuria Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Drug Type, 2020-2035
    • 15.2.1. Nitisinone (p-hydroxyphenyl-pyruvate dioxygenase inhibitor)
    • 15.2.2. Pain Relief Medication
    • 15.2.3. Dietary Supplements
  • 15.3. Market Value Forecast By Route of Administration, 2020-2035
    • 15.3.1. Oral
    • 15.3.2. Topical
    • 15.3.3. Parenteral
  • 15.4. Market Value Forecast By Patient Age Group, 2020-2035
    • 15.4.1. Pediatric
    • 15.4.2. Adult
    • 15.4.3. Geriatric
  • 15.5. Market Value Forecast By Distribution Channel, 2020-2035
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Retail Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast By Country / Sub-region, 2020-2035
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Drug Type
    • 15.7.2. By Route of Administration
    • 15.7.3. By Patient Age Group
    • 15.7.4. By Distribution Channel
    • 15.7.5. By Country / Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2024)
  • 16.3. Company Profiles
    • 16.3.1. Swedish Orphan Biovitrum AB
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Eton Pharmaceuticals
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. Johnson & Johnson Services, Inc.
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Pfizer Inc.
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. GSK plc
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Sanofi
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Mallinckrodt Pharmaceuticals
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Teva Pharmaceutical Industries Ltd.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Bristol Myers Squibb
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Sun Pharmaceutical Industries Ltd.
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. Cipla
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments
    • 16.3.12. Dr. Reddy's Laboratories Ltd.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Financial Overview
      • 16.3.12.3. Product Portfolio
      • 16.3.12.4. Business Strategies
      • 16.3.12.5. Recent Developments